(0.51%) 5 072.00 points
(0.40%) 38 222 points
(0.62%) 17 547 points
(0.62%) $79.49
(1.14%) $1.954
(0.55%) $2 323.70
(0.08%) $26.77
(1.45%) $968.70
(0.03%) $0.933
(-0.06%) $11.02
(-0.08%) $0.798
(-0.40%) $92.89
Live Chart Being Loaded With Signals
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States...
Stats | |
---|---|
今日成交量 | 601.00 |
平均成交量 | 5 980.00 |
市值 | 2.41M |
EPS | $-0.0600 ( 2023-10-16 ) |
下一个收益日期 | ( $0 ) 2024-06-03 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.670 |
ATR14 | $0 (0.00%) |
Intellipharmaceutics 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Intellipharmaceutics 财务报表
Annual | 2023 |
营收: | $65 728.00 |
毛利润: | $65 728.00 (100.00 %) |
EPS: | $-0.0874 |
FY | 2023 |
营收: | $65 728.00 |
毛利润: | $65 728.00 (100.00 %) |
EPS: | $-0.0874 |
FY | 2022 |
营收: | $65 728.00 |
毛利润: | $-190 726 (-290.17 %) |
EPS: | $-0.0983 |
FY | 2020 |
营收: | $1.40M |
毛利润: | $1.40M (100.00 %) |
EPS: | $-0.140 |
Financial Reports:
No articles found.
Intellipharmaceutics
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。